AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
AstraZeneca (AZN) Acquires Biologics Manufacturing Facility from Amgen (AMGN)
September 11, 2015 7:02 AM EDTAstraZeneca (NYSE: AZN) added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc (Nasdaq: AMGN). Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the companys extensive portfolio of biologics medicines.
AstraZeneca plans to start staffing the facility immediately to... More
